20 Largest Medical Device Companies by Revenue and Growth

Medical technology is one of the most resilient industries in healthcare. Stents, insulin pumps, surgical robots, MRI scanners, hip implants, and dialysis machines keep working through economic cycles because patients still need care. Global medtech sales exceed $500 billion by most industry estimates, and the sector has grown steadily as populations age.

The top medical device companies range from diversified giants with tens of billions in annual sales to focused innovators growing at double digit rates. Comparing them is harder than it looks. Rankings depend on fiscal year, currency conversion, and whether a diversified healthcare group reports device revenue separately from drugs, diagnostics, or consumer goods.

Top 20 Medical Devices Companies: Latest Reported Revenue, Fiscal Year, & Categories

Figures use each company’s own most recent full year reporting found at the time of writing, converted to dollars at approximate rates where noted. Ranks 7 through 10 and 13 through 16 are close enough that exchange rates and segment definitions can reorder them. The Abbott, B. Braun, Terumo, and Olympus entries rest on approximations and should be confirmed from annual reports.

Top 20 Medical Device Companies

The global medical device industry spans surgical robotics, cardiovascular interventions, diagnostic imaging, diabetes management, orthopaedics, ophthalmology, respiratory care, and connected hospital technologies. The companies profiled below represent major participants across these markets, with business models ranging from equipment sales and recurring surgical consumables to implantable devices, diagnostic sensors, and software supported care.

Financial figures refer to the stated reporting period and are not directly comparable in every case because fiscal years, business segments, acquisition effects, and currency movements differ. The list is an editorial selection of prominent medical technology companies, not a strict ranking by market capitalization or device revenue.

1. Medtronic

Medtronic is one of the world’s largest medical technology companies, with operations spanning cardiovascular care, neuroscience, medical surgery, and diabetes management. For fiscal 2026, the company reported revenue of approximately $36.4 billion, according to the supplied financial figures, with reported growth of 8.4 percent and organic growth of 5.8 percent. Adjusted earnings per share reached $5.53, while free cash flow totaled approximately $5.4 billion.

The business benefits from a broad installed base of devices and recurring revenue from replacement components, procedure related products, and long term patient management. Its scale also supports investment in research, clinical evidence, manufacturing capacity, and global distribution. These advantages are particularly important in regulated markets where hospitals require dependable product supply and extensive clinical validation.

Products and recent advances

Medtronic’s portfolio includes cardiac pacemakers, defibrillators, heart valves, catheter based ablation systems, spinal implants, surgical instruments, and neuromodulation devices. The Affera Sphere 9 platform combines pulsed field ablation and radiofrequency capabilities for treating certain cardiac arrhythmias. Its Hugo robotic assisted surgery system is another strategic growth platform, while Symplicity renal denervation targets selected patients with uncontrolled hypertension.

The company also develops the Stealth AXiS surgical navigation and robotic assistance platform for spine procedures. These technologies address clinical areas where physicians increasingly seek more precise interventions, improved procedural efficiency, and alternatives to conventional surgery.

What it is working on now

Medtronic is expanding its cardiac ablation business, developing additional indications for Hugo, and pursuing wider adoption of renal denervation and neuromodulation. The separation of its diabetes business through the MiniMed public offering also represents a significant portfolio change.

Commercial success will depend on clinical outcomes, physician training, reimbursement, and the ability to compete against established robotic surgery providers. Tariffs, hospital capital spending, and competition in transcatheter heart valve procedures remain important considerations. Its strategic challenge is to convert promising technologies into sustainable, profitable businesses without compromising its broad established product base.

2. Johnson & Johnson MedTech

Johnson & Johnson MedTech reported 2025 sales of approximately $33.8 billion, representing growth of 6.1 percent. Its major businesses include surgery, orthopaedics, cardiovascular technologies, and electrophysiology. Surgery generated approximately $10.1 billion, orthopaedics $9.3 billion, and cardiovascular products $8.9 billion. Acquisitions have strengthened the cardiovascular portfolio, particularly through Abiomed’s circulatory support technologies and Shockwave Medical’s intravascular lithotripsy platform.

These businesses provide access to different stages of cardiovascular treatment, from supporting the heart during high risk procedures to treating heavily calcified arteries. The company’s global sales organization and established relationships with hospitals provide significant commercial advantages, although performance varies by product category and geographic market.

Products and recent advances

The portfolio includes Impella heart pumps, Shockwave intravascular lithotripsy systems, Biosense Webster electrophysiology equipment, Ethicon surgical instruments, and DePuy Synthes joint replacement implants. Its Velys robotic technology supports selected orthopaedic procedures, while the Ottava robotic surgical system represents an effort to compete in soft tissue surgery.

Cardiovascular electrophysiology is particularly important because hospitals are expanding treatment capacity for atrial fibrillation and other heart rhythm disorders. The combination of mapping equipment, catheters, implants, and procedure related products creates opportunities to serve multiple clinical needs within the same hospital account.

What it is working on now

Johnson & Johnson is prioritizing cardiovascular interventions, surgical robotics, and technologies that can improve procedural precision. Its planned separation of DePuy Synthes into a standalone orthopaedics company, targeted for completion by mid 2027, would create a more focused MedTech business. The strategy could give the remaining business greater emphasis on cardiovascular care and surgery, while allowing orthopaedics to pursue its own investment priorities.

However, robotics requires substantial development spending, surgeon training, and hospital capital investment. The company must also demonstrate that newer platforms offer practical advantages over existing systems. Competition, pricing pressure, and uneven international demand will influence how quickly these investments translate into stronger sales.

3. Siemens Healthineers

Siemens Healthineers reported approximately €23.4 billion in revenue for fiscal 2025, with comparable revenue growth of 5.9 percent and an adjusted EBIT margin of 16.5 percent. Adjusted earnings before interest and taxes approached €3.9 billion, while free cash flow reached approximately €2.7 billion. Imaging remains the company’s largest business, supported by demand for computed tomography, magnetic resonance imaging, X ray systems, and image guided procedures. Varian adds a major oncology business focused on radiotherapy and cancer treatment technologies.

The company also supplies laboratory diagnostic equipment, although this business has faced weaker market conditions than imaging. Its performance is influenced by hospital investment cycles, equipment replacement demand, service contracts, and the ability of healthcare providers to finance increasingly sophisticated diagnostic infrastructure.

Products and recent advances

The Naeotom Alpha photon counting CT system is a major technological development, using a different detector approach to capture detailed anatomical information and potentially improve dose efficiency for suitable examinations. Its broader portfolio includes MRI scanners, ultrasound, angiography, laboratory diagnostics, and Varian radiotherapy systems.

AI Rad Companion and related software support image analysis and workflow automation. These products illustrate a shift in medical imaging from selling individual scanners toward providing integrated diagnostic environments that combine equipment, software, clinical applications, and long term service.

What it is working on now

Siemens Healthineers is expanding photon counting CT, integrating AI into imaging workflows, and working to improve the profitability of its diagnostics business. Its commercial opportunity depends on proving that newer systems can improve diagnostic confidence, throughput, or total operating costs sufficiently to justify replacement spending. Hospitals also increasingly evaluate interoperability, cybersecurity, equipment uptime, and lifetime service expenses when purchasing imaging systems.

Tariffs and currency movements can affect margins because the company operates globally. The parent Siemens group’s ownership position is another corporate factor, but operationally the key priority remains converting its technology advantage into stronger adoption and sustainable returns.

4. Stryker

Stryker generated approximately $25.1 billion in 2025 net sales, with reported growth of 11.2 percent and organic growth of 10.3 percent. MedSurg and Neurotechnology contributed approximately $15.6 billion, while orthopaedics generated about $9.5 billion. Adjusted earnings per share reached $13.63. The company benefits from a diversified portfolio serving operating rooms, emergency departments, intensive care units, and orthopaedic surgery centers.

Its products include hospital beds, surgical instruments, endoscopy equipment, neurotechnology systems, and joint replacement implants. This combination provides multiple revenue opportunities within hospitals, while its installed equipment base supports additional sales of service, accessories, and replacement products. Stryker’s recent growth has also benefited from strong procedural demand and acquisitions that broaden its access to specialist markets.

Products and recent advances

Mako robotic assisted surgery is a central competitive platform, supporting selected knee and hip replacement procedures through preoperative planning and robotic guidance. Stryker also supplies Triathlon knee implants, surgical power tools, endoscopy systems, and Vocera communication technologies. Its acquisition of Inari Medical expanded its presence in mechanical thrombectomy, particularly treatments for blood clots in the venous system.

This provides an additional cardiovascular and vascular intervention opportunity alongside the company’s established orthopaedic business. Product differentiation increasingly depends on clinical workflow, implant performance, surgeon familiarity, and the ability to demonstrate value to hospitals.

What it is working on now

Stryker is integrating Inari Medical, expanding the Mako platform across additional procedures, and strengthening its presence in ambulatory surgery centers. These facilities are important because selected procedures are increasingly performed outside traditional inpatient hospitals, creating demand for appropriately sized equipment and efficient operating workflows. Stryker must also maintain innovation across its established businesses while managing acquisition costs and international expansion.

Robotic surgery remains competitive, particularly as other manufacturers introduce new systems. Sustained growth will depend on adoption by surgeons, purchasing decisions by hospital groups, and the financial benefits customers can achieve through improved procedural consistency and operating room efficiency.

5. Becton Dickinson (BD)

Becton Dickinson, commonly known as BD, reported fiscal 2025 revenue of approximately $21.8 billion before its portfolio restructuring. The company has historically combined medical supplies, medication delivery systems, laboratory diagnostics, and biosciences. Its large installed base and broad product distribution network make it an important supplier to hospitals, laboratories, pharmacies, and outpatient facilities.

However, the company’s business composition changed significantly when its biosciences and diagnostics operations were combined with Waters Corporation in a transaction completed in early 2026. This distinction matters because historical consolidated revenue is not a direct measure of the smaller continuing business. BD’s future financial profile is increasingly centered on medical supplies, medication management, and interventional technologies rather than its former combination of medical and laboratory businesses.

Products and recent advances

BD supplies syringes, needles, vascular access devices, infusion pumps, medication dispensing cabinets, and urinary management products. Its Alaris infusion systems support controlled medication delivery, while Pyxis automated dispensing cabinets help hospitals manage medication storage and distribution. PureWick offers a noninvasive urine collection option for selected patients, and Libertas is a wearable injector platform designed for certain drug delivery applications.

These products serve recurring clinical needs, giving BD exposure to medication administration volumes, hospital automation investment, and demand for safer workflows. The commercial value increasingly comes from integrating devices into hospital information systems and reducing medication errors or manual work.

What it is working on now

The more focused BD business is working to strengthen connected medication delivery, improve infusion technology, and allocate capital following the diagnostics transaction. Proceeds from the separation can support debt reduction and potential share repurchases, although final capital allocation depends on management decisions and financial conditions.

Operational priorities include manufacturing reliability, supply chain resilience, and managing input costs. BD also faces competition from other infusion and medication management suppliers, making software integration, device usability, and service support important differentiators. The central strategic question is whether a more concentrated portfolio can deliver stronger margins and clearer growth than the previous diversified structure.

6. Philips

Philips reported 2025 group sales of approximately €17.8 billion, comparable sales growth of 2 percent, and an adjusted EBITA margin of 12.3 percent. Free cash flow was approximately €512 million. Its three main businesses are Diagnosis and Treatment, Connected Care, and Personal Health. Imaging and image guided therapy serve hospitals, Connected Care includes patient monitoring and sleep and respiratory care, and Personal Health includes consumer products such as Sonicare.

The company has been working to improve profitability through productivity initiatives and operational restructuring. Its financial performance must be considered alongside the substantial quality, regulatory, and legal challenges associated with the Respironics respiratory device recall, which continue to influence corporate priorities and investor assessments.

Products and recent advances

Philips supplies MRI, CT, ultrasound, image guided therapy equipment, patient monitors, and sleep apnea treatment devices. Its imaging portfolio supports complex procedures, while connected monitoring systems help clinicians track patients across hospital departments. AI enabled applications can assist with image acquisition, workflow prioritization, and selected clinical tasks.

Personal Health products provide a consumer facing business with different demand patterns from hospital equipment. The combined portfolio allows Philips to sell hardware, software, maintenance, and related services, but product reliability and clinical usability remain fundamental to customer confidence.

What it is working on now

Philips is rebuilding trust through quality management, regulatory compliance, product remediation, and stronger operational controls. It is also integrating AI into imaging and patient monitoring while seeking improved margins and more consistent sales growth. The company must balance innovation with the need to demonstrate that safety and quality systems are dependable. Hospital purchasing decisions often involve long evaluation cycles, so reputation can influence sales well beyond the immediate cost of a product recall.

Philips’ ability to deliver sustained recovery will depend on product execution, litigation costs, operational efficiency, and evidence that new technologies improve clinical workflow without adding unnecessary complexity. Its recovery should therefore be judged on both financial performance and measurable progress in quality and reliability.

7. Abbott Laboratories: Medical Devices

Abbott reported total sales of approximately $44.3 billion in 2025, with medical devices representing a major growth engine. Fourth quarter medical device sales increased 10.4 percent organically, according to the company’s results. Continuous glucose monitoring is particularly important, with FreeStyle Libre generating more than $7.5 billion in annual sales based on the supplied figures. Abbott’s wider corporate portfolio also includes diagnostics, nutrition, and established pharmaceuticals, so total company revenue should not be confused with medical device revenue alone.

The company benefits from serving both chronic disease management and hospital based specialties, with recurring sensor purchases complementing implantable devices and procedure related products. Its acquisition of Exact Sciences in March 2026 further expanded its overall healthcare portfolio, although cancer diagnostics are distinct from medical devices.

Products and recent advances

Abbott’s device portfolio includes FreeStyle Libre continuous glucose monitoring, the Lingo consumer biosensor, MitraClip and TriClip structural heart technologies, electrophysiology equipment, cardiac rhythm management devices, and neuromodulation systems. Continuous glucose monitoring provides patients and clinicians with frequent glucose readings without the repeated fingerstick testing associated with traditional approaches.

Structural heart products support less invasive treatment options for selected patients with valve disease. The company’s combination of sensors, software, implants, and catheter based technologies gives it exposure to several important medical trends, including chronic disease monitoring and minimally invasive cardiovascular care.

What it is working on now

Abbott is expanding sensor adoption, developing additional cardiovascular technologies, and integrating Exact Sciences into its broader healthcare business. Its priorities include increasing access to continuous glucose monitoring, strengthening its presence in electrophysiology, and broadening structural heart treatment options. Competition with Dexcom and other glucose monitoring suppliers makes sensor accuracy, wear duration, affordability, reimbursement, and ease of use important commercial factors.

Meanwhile, cardiovascular growth depends on clinical evidence, physician training, and hospital adoption. Abbott’s diverse corporate portfolio can provide resilience, but results from nutrition and diagnostics can still influence consolidated growth. Evaluating its medical device performance therefore requires separating the device segment from the company’s other businesses.

8. GE HealthCare

GE HealthCare reported 2025 revenue of approximately $20.6 billion, representing growth of 4.8 percent. Organic revenue increased 3.5 percent, while the company recorded approximately $2.1 billion in net income and $3.2 billion in adjusted EBIT. Its business covers imaging, ultrasound, patient monitoring, pharmaceutical diagnostics, and advanced visualization solutions. A large installed base of hospital equipment creates recurring service and maintenance opportunities, while new equipment sales depend heavily on hospital budgets and replacement cycles.

GE HealthCare also benefits from its presence in radiopharmaceuticals and molecular imaging, which connect diagnostic equipment with specialized agents used in medical examinations. Tariffs affected profitability in 2025, demonstrating how manufacturing location and international trade can influence the economics of medical technology companies.

Products and recent advances

The company supplies CT scanners, MRI systems, X ray equipment, ultrasound machines, molecular imaging systems, and patient monitoring technologies. Flyrcado is a PET myocardial perfusion imaging agent used in evaluating selected patients with suspected coronary artery disease.

GE HealthCare has also introduced Photonova Spectra, a photon counting CT platform, and announced a proposed acquisition of Intelerad to expand enterprise imaging software and cloud based workflow capabilities. Together, these products demonstrate a strategy that combines imaging hardware, specialized diagnostic agents, and digital systems for managing medical images across healthcare networks.

What it is working on now

GE HealthCare is pursuing precision medicine, radiopharmaceutical development, photon counting CT, and AI enabled imaging and ultrasound. Its investment in enterprise imaging reflects a wider market shift toward centralized image management and collaboration across hospitals and outpatient centers. The company must demonstrate that these technologies improve diagnostic performance, clinician productivity, or the economics of care.

Capital spending constraints can delay equipment purchases, while tariffs and currency movements can reduce margins. The proposed Intelerad transaction also makes integration and execution important considerations. Long term growth will depend on expanding the installed base, generating service revenue, and ensuring that advanced imaging systems deliver practical benefits rather than simply higher technical specifications.

9. Boston Scientific

Boston Scientific reported 2025 net sales of approximately $20.074 billion, up 19.9 percent on a reported basis and 15.8 percent organically. This strong performance reflected growth across several interventional specialties and the expansion of its electrophysiology business. The company operates in cardiovascular interventions, electrophysiology, peripheral vascular treatment, endoscopy, urology, and neuromodulation.

Unlike manufacturers that depend heavily on large capital equipment purchases, Boston Scientific generates substantial revenue from catheters, implants, and other products consumed during procedures. This model creates repeat purchasing opportunities as procedure volumes rise. Acquisitions have also expanded its portfolio, but the company must continue to integrate new technologies while maintaining the clinical performance and physician relationships that support its existing franchises.

Products and recent advances

Farapulse is a major pulsed field ablation platform used in treating selected patients with atrial fibrillation. Pulsed field ablation uses electrical energy to target cardiac tissue and has become an important area of competition in electrophysiology. Watchman provides left atrial appendage closure for selected patients with atrial fibrillation who require an alternative approach to stroke prevention.

Other products include peripheral vascular intervention devices, endoscopy systems, urology products, and neuromodulation technologies. The breadth of the portfolio enables Boston Scientific to participate in several high value procedure markets rather than relying on one product category.

What it is working on now

Boston Scientific is expanding its electrophysiology portfolio, building clinical evidence for Watchman, and developing new catheter and mapping technologies. It is also pursuing acquisitions to add differentiated products and strengthen its position in attractive treatment categories. Growth opportunities include increased use of minimally invasive cardiovascular procedures and greater adoption of technologies that help physicians treat complex conditions.

However, the company faces intense competition from Abbott, Medtronic, Johnson & Johnson, and specialist device manufacturers. Sustained performance will depend on product differentiation, reimbursement, clinical outcomes, and the ability to integrate acquired businesses without weakening profitability. Manufacturing capacity and regulatory approvals will also determine how quickly new products can contribute meaningful revenue.

10. Baxter International

Baxter is an established supplier of hospital products used in medication delivery, fluid management, patient care, and surgical treatment. Its continuing operations generated approximately $10.64 billion in 2024 sales, while the company underwent major portfolio changes during 2025. Its Kidney Care business was sold to Carlyle and now operates as Vantive, changing the composition of Baxter’s continuing business. This means historical revenue should not be compared directly with later figures without accounting for the divestiture.

Baxter’s position is supported by essential products used across hospitals, but the company has faced pressure to improve profitability, simplify operations, and strengthen supply reliability. Its experience also illustrates how a disruption at a major manufacturing facility can have consequences for healthcare systems far beyond the affected company.

Products and recent advances

Baxter supplies intravenous solutions, infusion pumps, hospital beds, patient monitoring equipment, and surgical products. The Novum IQ infusion platform supports controlled medication delivery, while Hillrom technologies provide hospital beds and patient monitoring systems. Intravenous fluids remain a critical product category because they are used across emergency care, surgery, intensive care, and routine hospital treatment.

the damage caused by Hurricane Helene to Baxter’s North Cove facility in 2024 highlighted the vulnerability of concentrated manufacturing networks. The episode demonstrated that manufacturing resilience, inventory planning, and alternative production capacity are important commercial and public health considerations.

What it is working on now

Baxter is focused on restoring operational stability, improving manufacturing reliability, managing costs, and strengthening the financial performance of its continuing businesses. Simplifying the portfolio gives management a clearer opportunity to prioritize hospital products and capital allocation.

However, recovery requires more than reducing expenses. Hospitals need reliable delivery of essential supplies, while customers also expect dependable equipment, technical support, and competitive pricing. Baxter must balance restructuring with investment in production capacity and product development. The company’s longer term prospects depend on improving execution, rebuilding financial flexibility, and demonstrating that its remaining portfolio can generate consistent cash flow without recurring supply disruptions.

11. Alcon

Alcon reported 2025 net sales of approximately $10.3 billion, with surgical products contributing about $5.8 billion and Vision Care approximately $4.6 billion. The company operates across cataract surgery, vitreoretinal procedures, refractive surgery, contact lenses, and ocular health. Its scale is supported by established relationships with ophthalmologists, optometrists, hospitals, and optical retailers. Alcon’s products address both surgical treatment and everyday vision correction, providing exposure to different customer groups and purchasing patterns.

Surgical equipment and implant sales are influenced by procedure volumes, while contact lenses and ocular health products benefit from recurring consumer demand. The company reported approximately $1.7 billion in free cash flow for 2025 and guided to continued sales growth in 2026, although currency effects, tariffs, and competitive pricing remain important factors.

Products and recent advances

Alcon’s portfolio includes PanOptix Pro premium intraocular lenses, cataract and vitreoretinal surgical systems, Precision7 and Total30 contact lenses, and ocular health treatments. Its Unity surgical platforms support cataract and vitreoretinal procedures, helping surgeons manage different stages of ophthalmic surgery.

Tryptyr, approved in 2025, added a treatment option for dry eye disease. These products address a market shaped by population ageing, rising demand for cataract surgery, increasing screen use, and greater interest in premium vision correction. Product performance, clinician familiarity, and patient outcomes remain central to adoption.

What it is working on now

Alcon is expanding its premium lens portfolio, developing dry eye treatments, and investing in surgical technology and contact lens innovation. The commercial challenge is to persuade healthcare providers and patients that new products offer meaningful improvements over established alternatives. Premium lenses can support higher value sales, but adoption depends on patient suitability, affordability, and surgeon recommendations.

Contact lens growth is influenced by comfort, convenience, replacement schedules, and competition from other major brands. Alcon also needs to manage manufacturing costs and tariffs while maintaining research investment. Its long term opportunity lies in combining surgical leadership with recurring vision care products, creating a broader relationship with eye care professionals and patients.

12. Intuitive Surgical

Intuitive Surgical reported approximately $10.06 billion in 2025 revenue, up 21 percent from the previous year. Instruments and accessories generated about $6.02 billion, while systems contributed approximately $2.47 billion. Around 3.15 million da Vinci procedures were performed during the year, illustrating the scale of the company’s robotic surgery ecosystem. Its business model combines the placement of robotic systems with recurring sales of instruments, accessories, and services.

This installed base creates a competitive advantage because hospitals invest in staff training, operating room workflows, and long term maintenance. However, new system placements depend on capital budgets and clinical demand, while procedural growth depends on surgeon adoption, patient selection, reimbursement, and evidence supporting robotic assisted approaches.

Products and recent advances

The da Vinci 5 platform adds enhanced computing capabilities and force feedback features designed to improve surgeon awareness during selected procedures. The Ion robotic platform supports minimally invasive bronchoscopy and lung nodule biopsy. Intuitive also offers training simulators, digital performance tools, and case analysis software.

These products form an integrated ecosystem rather than a standalone robotic machine. Instruments, software, maintenance, and education help support recurring revenue and customer retention. The company’s established position provides advantages in training and clinical experience, although competing manufacturers are developing alternatives for soft tissue surgery.

What it is working on now

Intuitive is expanding da Vinci 5 placements, increasing international adoption, and developing digital tools that support operating room efficiency and surgeon training. It also faces competition from Medtronic’s Hugo and Johnson & Johnson’s Ottava, which could influence hospital purchasing decisions and pricing over time.

To maintain leadership, Intuitive must demonstrate measurable clinical or workflow benefits and ensure that hospitals can justify the cost of robotic surgery programs. Its recurring consumables model remains a major strength, but future growth will depend on procedure volumes, new indications, manufacturing capacity, and the ability to make robotic surgery economically attractive to a broader range of healthcare providers.

13. B. Braun

B. Braun is a privately held German medical technology company founded in 1839. It reported 2025 sales of approximately €9.396 billion, an increase of 2.8 percent in reported currency and 5.1 percent at constant exchange rates. The company employed approximately 66,800 people at year end and invested about €584 million in research and development. Its principal businesses cover hospital care, intravenous therapy, surgical technologies, and dialysis.

Private ownership means that its financial reporting differs from that of publicly listed competitors, but its annual reports provide useful evidence of its scale and investment priorities. Its broad consumables portfolio also makes it an important supplier to healthcare systems that need reliable access to routine medical products and specialized treatment equipment.

Products and recent advances

The portfolio includes infusion pumps, intravenous catheters such as Introcan, surgical instruments through Aesculap, dialysis equipment through Avitum, and products for wound care and medication delivery. These technologies serve routine hospital operations as well as specialized treatment settings.

B. Braun’s competitive position is built on product reliability, broad clinical coverage, and long standing relationships with healthcare providers. Its offerings increasingly connect equipment, consumables, digital applications, and services, helping hospitals standardize clinical workflows and manage supplies more effectively.

What it is working on now

B. Braun is investing in connected care, production capacity, digital hospital integration, and improvements to supply chain resilience. Its 2025 investment in sites and technologies exceeded €800 million, reflecting a focus on manufacturing infrastructure and future product development. The company also increased research and development spending, supporting efforts to improve product performance and develop integrated clinical solutions.

Major market considerations include hospital cost pressures, competition from multinational suppliers, regional procurement requirements, and sustainability expectations. B. Braun’s long term advantage depends on maintaining dependable supply, supporting clinicians with effective products, and using its broad portfolio to build deeper relationships with hospitals across Europe, North America, and Asia.

14. Zimmer Biomet

Zimmer Biomet reported 2025 net sales of approximately $8.232 billion, up 7.2 percent on a reported basis and 3.9 percent on an organic constant currency basis. Its fourth quarter revenue reached about $2.244 billion. The company specializes in musculoskeletal healthcare, including joint replacement, trauma products, sports medicine, and surgical technologies. Its business is closely linked to procedure volumes, population ageing, the prevalence of osteoarthritis, and patient access to elective surgery.

Acquisitions have expanded its portfolio, but reported growth must be separated from underlying performance when evaluating its competitive position. Zimmer Biomet operates in a market where surgeon preference, implant performance, hospital contracts, and robotic assistance can influence purchasing decisions over many years.

Products and recent advances

The company’s portfolio includes Persona knee implants, hip replacement systems, ROSA robotic assisted surgery technology, trauma devices, and sports medicine products. Its acquisition of Paragon 28 expanded its foot and ankle business, giving the company access to a specialist market beyond traditional large joint replacement.

Zimmer Biomet has also pursued robotic knee technology through its planned acquisition of Monogram Technologies. These products support a broader strategy of combining implants, surgical planning, robotics, and digital tools to serve orthopaedic surgeons across different procedures.

What it is working on now

Zimmer Biomet is expanding ROSA adoption, integrating Paragon 28, and strengthening its data and technology offerings. It must also compete effectively in knee and hip replacement, where Stryker’s Mako and other established systems have strong surgeon relationships. Robotic platforms can differentiate a company, but adoption depends on evidence, training, capital investment, and whether hospitals can achieve better procedural consistency or operating efficiency.

The integration of acquired products adds commercial opportunities but also creates execution risks. Long term growth will depend on implant innovation, improved access to surgical technologies, and the ability to translate its expanded portfolio into stronger organic sales and sustainable profitability.

15. Terumo

Terumo is a major Japanese medical technology company with businesses spanning cardiovascular interventions, medical care solutions, and blood and cell technologies. Its operations cover products used in hospitals, catheter based procedures, blood collection, transfusion, and specialized cellular therapies.

Revenue should be taken from the relevant fiscal year in its latest annual reporting rather than relying on a rounded historical estimate, because exchange rates and segment performance affect comparisons. Terumo’s business model combines recurring consumables with specialized equipment and higher value interventional products. Its international reach also provides access to growing demand for minimally invasive cardiovascular care, although regulatory requirements and regional procurement conditions can influence the speed of expansion.

Products and recent advanceS

Terumo supplies radial access sheaths, catheters, guidewires, stents, and the TR Band compression device used after selected procedures performed through the wrist artery. Its aortic intervention products address vascular conditions requiring specialized catheter based treatment.

The Blood and Cell Technologies business supplies apheresis systems and equipment used in blood processing and certain cell therapy manufacturing processes. These products connect Terumo to several markets, including cardiovascular intervention, blood component collection, and the infrastructure needed to manufacture advanced therapies. Their commercial value depends on reliability, clinical performance, and compatibility with hospital workflows.

What it is working on now

Terumo is pursuing growth in cardiovascular intervention, aortic treatment, cell and gene therapy manufacturing, and drug delivery. The expansion of minimally invasive procedures creates opportunities for catheters and other single use products, while advanced therapy manufacturing may increase demand for specialized collection and processing systems.

The company must also navigate different regulatory pathways and clinical adoption patterns across markets. Acquisitions can add technology and geographic reach, but integration and capital allocation remain important. Its longer term growth will depend on innovation, manufacturing capacity, and the ability to demonstrate that its products improve procedural performance and meet the evolving needs of hospitals and specialist treatment centers.

16. Olympus

Olympus is a Japanese medical technology company best known for gastrointestinal endoscopy and related therapeutic instruments. It sold its scientific solutions business, now operating as Evident, in 2023 to concentrate on medical technology. The company’s financial performance should be assessed using its latest fiscal year results and medical business reporting, rather than an unverified rounded revenue estimate.

Olympus occupies an important position in endoscopy, where hospitals and clinics rely on equipment for gastrointestinal examinations, diagnosis, biopsy, and minimally invasive treatment. Revenue opportunities include endoscopes, compatible instruments, service contracts, and replacement equipment. The business also faces substantial quality and regulatory responsibilities because endoscopes are reusable devices that require effective cleaning, maintenance, and infection control procedures.

Products and recent advances

The EVIS X1 endoscopy platform provides imaging technologies designed to support the examination of gastrointestinal conditions. Olympus also supplies endoscopic instruments, surgical products, urology devices, and selected single use scopes.

Image enhancement can help clinicians assess tissue and identify areas requiring closer examination, while therapeutic accessories support procedures performed through minimally invasive routes. The company’s installed base and physician familiarity provide advantages, but product reliability, reprocessing requirements, and the availability of effective technical support are central to hospital purchasing decisions.

What it is working on now

Olympus is pursuing quality system improvements, regulatory compliance, endoscopy innovation, and the development of products that support more efficient clinical workflows. It has faced regulatory scrutiny, including FDA warning letters, making manufacturing controls and corrective action important parts of its strategy. Single use endoscopes may offer benefits in selected settings by reducing reliance on reprocessing, although cost and environmental considerations affect adoption.

Olympus must also show that new imaging technologies offer practical clinical value. Its future performance depends on rebuilding confidence where necessary, strengthening product quality, and maintaining its position in a competitive global endoscopy market.

17. Edwards Lifesciences

Edwards Lifesciences reported 2025 sales growth of 11.5 percent, with transcatheter aortic valve replacement remaining its core business. TAVR sales and transcatheter mitral and tricuspid therapies provide exposure to structural heart disease, particularly in patients who may benefit from less invasive alternatives to open heart surgery.

The company has increasingly focused its portfolio on structural heart technologies, following the separation of its critical care business. Its growth depends on clinical evidence, regulatory approvals, physician training, and the ability of healthcare systems to identify suitable patients. The expansion of treatment into additional patient groups can increase market opportunity, but adoption requires careful evaluation of clinical outcomes, procedural risks, and long term durability.

Products and recent advances

The SAPIEN valve platform is a major product in TAVR, which allows selected patients with aortic valve disease to receive a replacement valve through a catheter based procedure. Edwards also offers EVOQUE for transcatheter tricuspid valve replacement, PASCAL for valve repair, and the SAPIEN M3 platform for transcatheter mitral valve replacement.

These products address different structural heart conditions and may help physicians treat patients who face elevated risks from conventional surgery. Their commercial importance depends on strong clinical evidence, reliable delivery systems, and reimbursement for the procedures involved.

What it is working on now

Edwards is expanding structural heart treatment options, supporting the adoption of mitral and tricuspid therapies, and studying patients who may benefit from earlier intervention. Its 2026 outlook anticipated sales growth of 8 to 10 percent at constant currency, with the transcatheter mitral and tricuspid therapies business expected to grow faster than the overall company.

The company must continue demonstrating the clinical and economic value of these treatments while expanding physician training and access. Its planned acquisition of JenaValve did not close, highlighting the execution risks associated with portfolio expansion. Future growth will depend on clinical results, regulatory progress, and the pace at which hospitals adopt newer structural heart procedures.

18. ResMed

ResMed reported record fourth quarter fiscal 2026 revenue of approximately $1.5 billion, up 9 percent, for the quarter ended June 30, 2026. Its business focuses on sleep apnea treatment, respiratory care, and connected healthcare products. ResMed benefits from recurring demand for masks, replacement components, and digital services, alongside sales of CPAP machines and ventilatory support equipment. Its products address conditions that can require long term treatment and ongoing patient adherence.

Demand is influenced by diagnosis rates, access to sleep testing, insurance coverage, patient comfort, and awareness of sleep disordered breathing. The company also operates in a market affected by changing obesity treatment patterns and advances in connected care.

Products and recent advances

ResMed supplies CPAP and other positive airway pressure devices, masks, the Astral home ventilator, and cloud connected software used to support treatment monitoring. Its digital tools can help clinicians and providers assess usage patterns, identify adherence problems, and support patients during therapy.

The combination of devices and connected services is important because the effectiveness of sleep apnea treatment depends on consistent use. Product design therefore emphasizes comfort, ease of setup, reliable connectivity, and the ability to manage treatment outside traditional hospital settings.

What it is working on now

ResMed is expanding connected care, improving patient adherence tools, and evaluating how GLP 1 weight loss medications may influence sleep apnea diagnosis and treatment demand. Weight loss can improve sleep apnea for some patients, but it does not eliminate the need for treatment in every case.

The commercial effect will depend on clinical outcomes, diagnosis rates, and whether patients continue using respiratory devices. ResMed must also manage regulatory and product availability issues affecting certain ventilator products, including the temporary suspension of Astral sales referenced in earlier disclosures. Its long term prospects depend on maintaining product reliability, supporting patients over time, and extending access to effective respiratory care.

19. Dexcom

Dexcom reported 2025 revenue of approximately $4.66 billion, representing growth of 16 percent, and provided 2026 revenue guidance of approximately $5.16 billion to $5.25 billion. The company specializes in continuous glucose monitoring, a market that has expanded as diabetes care increasingly incorporates frequent glucose measurement and digital data sharing.

Revenue comes largely from sensors and related products, making sensor replacement cycles and patient adoption important commercial drivers. Dexcom competes in a market where clinical accuracy, ease of use, wear duration, affordability, and reimbursement influence purchasing decisions. Its growth strategy also includes reaching patients who do not use insulin and expanding the role of glucose data beyond traditional intensive diabetes management.

Products and recent advances

The G7 continuous glucose monitoring system provides glucose readings through a wearable sensor and compatible digital devices. The G7 15 Day system was cleared in the United States in 2025, extending wear duration for eligible users.

Stelo, an over the counter glucose biosensor, expands access for adults who meet its intended use criteria, including certain people with type 2 diabetes who do not use insulin. These products reflect a broader shift toward more accessible health monitoring, although over the counter glucose data should not be treated as a standalone diagnostic tool or a replacement for appropriate medical care.

What it is working on now

Dexcom is expanding access to continuous glucose monitoring, developing future sensor platforms, and competing with Abbott’s FreeStyle Libre portfolio. Product differentiation increasingly depends on accuracy, wear duration, usability, integration with digital health tools, and affordability.

The company must also maintain manufacturing quality and regulatory compliance while scaling production to serve a larger user base. Expansion into non insulin users and consumer monitoring could increase its addressable market, but willingness to pay and evidence of practical benefit will influence adoption. Sustainable growth will depend on retaining existing users, broadening reimbursement, and delivering reliable sensor performance at competitive costs.

20. Align Technology

Align Technology reported approximately $4.035 billion in 2025 revenue, up 0.9 percent, with clear aligners generating about $3.245 billion and imaging systems and services approximately $790 million. It shipped more than 2.61 million clear aligner cases during the year, representing growth of 4.7 percent. The company combines orthodontic treatment products with digital scanning and computer aided design technologies.

Its business depends on orthodontist and general dentist participation, patient demand for elective treatment, treatment affordability, and the ability to maintain a strong network of trained providers. Revenue growth has been relatively modest compared with some larger medical technology businesses, making product innovation, scanner adoption, and international expansion particularly important.

Products and recent advances

Invisalign clear aligners are the company’s flagship orthodontic product, supported by the iTero Lumina intraoral scanner and exocad digital dentistry software. These technologies allow dental professionals to capture digital impressions, plan treatment, and support selected restorative and orthodontic workflows.

Invisalign with mandibular advancement also extends the platform into specific treatment needs beyond conventional tooth alignment. The combination of scanning, planning software, and customized aligners creates an integrated digital workflow that can differentiate Align from providers offering only orthodontic appliances.

What it is working on now

Align is focused on expanding Invisalign adoption, increasing digital scanner penetration, improving treatment planning tools, and reaching younger and international patient groups. The commercial challenge is to maintain demand when consumers face higher living costs and may postpone elective dental treatment. Competition from other clear aligner manufacturers and lower cost treatment options also puts pressure on pricing.

Growth depends on the number of participating clinicians, patient conversion, treatment completion, and repeat referrals. Align’s digital ecosystem remains a strategic advantage, but continued investment must translate into improved clinical workflows and sustainable revenue growth rather than relying solely on brand recognition.

How the 20 Company Ranking Was Built

A fair ranking begins with clear inclusion rules. Otherwise, a conglomerate with massive total revenue will crowd out pure play device makers.

Inclusion Criteria

Companies qualify if medical device, medtech, or closely related diagnostic imaging revenue forms a substantial share of sales and can be estimated from public reporting. For diversified groups, only the relevant segment is counted. Johnson & Johnson is measured by its MedTech segment, and Abbott by its medical devices segment where available.

Exclusions

Several large firms are excluded or flagged. Medline Industries is primarily a distributor and manufacturer of supplies, which makes it not directly comparable. Danaher and Roche are dominated by diagnostics and life sciences or pharmaceuticals. Fresenius is largely a services business through dialysis clinics.

Fiscal Years and Currency

Fiscal years differ. Medtronic ends in April, Becton Dickinson in September, Siemens Healthineers in September, and Abbott in December. Euro and yen reporters are converted to U.S. dollars at approximate recent rates. Small changes in exchange rates can swap close ranks, so positions in the middle of the list should be read as tiers.

MedTech Companies Revenue Growth and Major Growth Drivers

What Is Driving Medical Device Industry Growth?

Aging Populations

The number of people aged 65 and older worldwide is projected to roughly double by 2050, according to United Nations estimates. Older adults need more joint replacements, cataract surgery, cardiac devices, and diagnostic imaging. That creates durable volume growth for orthopaedics, eye care, and cardiology companies.

Chronic Disease Burden

Heart disease, diabetes, kidney disease, and chronic respiratory conditions require long term device use. The International Diabetes Federation estimates more than 580 million adults live with diabetes globally. That scale supports continuous glucose monitors, insulin pumps, and dialysis equipment.

Minimally Invasive Procedures

Smaller incisions reduce pain and hospital stays. Catheter based procedures such as TAVR and pulsed field ablation have shifted care away from open surgery. Every step toward less invasive options expands the treatable patient pool.

Surgical Robotics

Robot assisted systems now cover soft tissue surgery, joint replacement, and spine procedures. They generate recurring revenue from instruments. New entrants are pushing prices and features, and hospitals are weighing capital costs against efficiency gains.

Diagnostics and Imaging

Advances like photon counting CT and AI image analysis improve detection. Healthcare systems also push for outpatient imaging to reduce costs. Radiology workforce shortages encourage AI enabled workflow tools.

Connected Devices and Remote Monitoring

Implantable devices, wearable patches, and home monitoring systems feed data to clinicians. Remote monitoring supports care at home and reduces readmissions. Cybersecurity and data privacy have become engineering priorities.

Diabetes Technology

Continuous glucose monitoring and automated insulin delivery are among the fastest growing categories. Over the counter CGMs broaden access. GLP-1 drugs may change the diabetes landscape, but experts still expect strong device demand.

Major MedTech Segments and Representative Companies

Risks and Regulatory Context

Medical devices are regulated by the FDA in the United States and by notified bodies under the European Union Medical Device Regulation. Recalls and warning letters can slow growth quickly, as Philips and Olympus have experienced. Tariffs, reimbursement changes, and hospital capital budgets also affect results.

Consolidation continues. Large players buy innovators to refill pipelines, and portfolio reshaping, including spinoffs of slower growing units, is increasingly common. Investors should note that revenue size does not equal growth or profitability.

Outlook for the Medical Devices Market Sector

Demographics, technology, reimbursement, and regulation will shape the medical devices market sector in the coming decade. Aging populations create steady demand, while AI, robotics, and sensors expand what devices can do. Payers push for evidence of cost effectiveness, which rewards devices that reduce hospital stays and complications.

The ranking itself will keep changing. Medtronic’s long tenure at the top is under pressure from J&J MedTech, and fast growers such as Boston Scientific, Intuitive, and Edwards are climbing. Readers following this industry should rely on annual reports and SEC filings, compare segments carefully, and always note the fiscal year behind a number.

FAQ

Q: What is the largest medical device company?

A: Medtronic is generally the largest pure play device company by revenue. Johnson & Johnson MedTech is close behind and may surpass it. Abbott is larger in total revenue but its device segment is smaller.

Q: Which medical device companies are growing fastest?

A: Intuitive Surgical, Boston Scientific, Edwards Lifesciences, and Dexcom have posted double digit growth. Their growth comes from robotics, cardiac ablation, structural heart, and glucose monitoring.

Q: What are the largest MedTech segments?

A: Cardiovascular, orthopaedics, imaging, diagnostics, and diabetes technology are among the largest. Surgical robotics is among the fastest growing.

Q: Which companies lead surgical robotics?

A: Intuitive Surgical leads soft tissue robotics with da Vinci. Stryker leads orthopaedic robotics with Mako. Medtronic, J&J, and Zimmer Biomet are expanding in the space.

Q: How are AI and digital health affecting medical devices?

A: AI improves imaging interpretation, workflow, and device performance. Connected devices enable remote monitoring. Regulators have authorized more than 1,000 AI enabled devices, mostly in imaging.

Q: Why do medical device rankings differ between sources?

A: Sources use different fiscal years, currency rates, and inclusion rules. Some count total company revenue, while others count only device segments.

Q: Are medical device companies a stable industry?

A: Demand is steady because many products treat chronic conditions. Companies still face recalls, tariffs, reimbursement shifts, and competition.

Q: Which company is the largest in diabetes devices?

A: Abbott and Dexcom lead continuous glucose monitoring. Medtronic’s MiniMed business is a major insulin pump player and is being separated.

Q: What regulates medical devices in the United States?

A: The FDA regulates devices through risk based pathways such as 510(k), De Novo, and premarket approval. Higher risk devices require more clinical evidence.